Adynxx Inc ADYX:OTCPK

RT Quote | Exchange | USD
Last | 02/25/21 EST
0.253UNCH (UNCH)
Volume
7
52 week range
0.05 - 2.40

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.253
  • 52 Week High2.40
  • 52 Week High Date01/07/21
  • 52 Week Low0.05
  • 52 Week Low Date09/23/20
  • Market Cap1.47M
  • Shares Out5.81M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta2.52
  • 1 Year % Change-76.57

RATIOS/PROFITABILITY

  • EPS (TTM)-3.54
  • P/E (TTM)-0.07
  • Fwd P/E (NTM)-1.49
  • EBITDA (MRQ)-7.309M
  • ROE (MRQ)-1,837.34%
  • Revenue (MRQ)460,000.00
  • Gross Margin (MRQ)24.13%
  • Net Margin (MRQ)-2,241.09%
  • Debt To Equity (MRQ)-79.02%

EVENTS

  • Earnings Date-
  • Ex Div Date05/06/2019
  • Div Amount6.30
  • Split Date-
  • Split Factor-

Latest Adynxx Inc News

There is no recent news for this security.

Latest ADYX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1....
Dennis Podlesak
Chairman
Rick Orr J.D.
Chief Executive Officer
Address
100 Pine St Ste 500
San Francisco, CA
94111-5103
United States